ArQule, Inc. and Daiichi Sankyo Co., Ltd. have entered into two agreements forming a strategic relationship for the development and discovery of new oncology therapeutics.     The two companies will co-develop ARQ 197, an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase, to treat cancer. They will also advance the application of ArQule’s kinase inhibitor discovery platform (AKIP) to develop a new generation of highly selective anti-cancer kinase inhibitors. ...